An Enhanced Delivery Ecosystem for Neurosurgery in 2020

COVID-19 UPDATE:

We wanted to provide a quick update on how EDEN2020 is progressing at the moment in regard to COVID-19. We are living in an unprecedented and constantly changing period. The extraordinary measures in place to contain the spreading of the coronavirus and assuring the safety of everyone is impacting our lives, and our work in many ways. To further ensure the safety and well-being of all, EDEN2020 clinical studies have been placed on hold.

This is not an isolated circumstance; many research programmes across Europe are also in similar situations and are impacted by the containment measures.

We are closely and constantly monitoring the situation. At the moment there is uncertainty on when and how our suspended activities will resume however the EDEN2020 consortium continue to work out mitigating measures.

We will provide another update when there are any changes.

For further information, the European Commission has placed up-to-date information on their website regarding COVID-19 response and action.

Yours sincerely,

Prof Ferdinando Rodriguez y Baena
Imperial College London
EDEN2020 coordinator and on behalf of the EDEN2020 consortium

—————————–

Due to an ageing population and the spiralling cost of brain disease in Europe and beyond, EDEN2020 aims to develop the gold standard for one-stop diagnosis and minimally invasive treatment in neurosurgery. Supported by a clear business case, it will exploit the unique track record of leading research institutions and key industrial players in the field of surgical robotics to overcome the current technological barriers that stand in the way of real clinical impact.

EDEN2020 will provide a step change in the modelling, planning and delivery of diagnostic sensors and therapies to the brain via flexible surgical access, with an initial focus on cancer therapy. It will engineer a family of steerable catheters for chronic disease management that can be robotically deployed and kept in situ for extended periods. The system will feature enhanced autonomy, surgeon cooperation, targeting proficiency and fault tolerance with a suite of technologies that are commensurate to the unique challenges of neurosurgery. Amongst these, the system will be able to sense and perceive intraoperative, continuously deforming, brain anatomy at unmatched accuracy, precision and update rates, and deploy a range of diagnostic optical sensors with the potential to revolutionise today’s approach to brain disease management. By modelling and predicting drug diffusion within the brain with unprecedented fidelity, EDEN2020 will contribute to the wider clinical challenge of extending and enhancing the quality of life of cancer patients – with the ability to plan therapies around delicate tissue structures and with unparalleled delivery accuracy.

EDEN2020 is strengthened by a significant industrial presence, which is embedded within the entire R&D process to enforce best practices and maximise translation and the exploitation of project outputs. As it aspires to impact the state of the art and consolidate the position of European industrial robotics, it will directly support the Europe 2020 Strategy.

Objectives, Approach and Impact

Partners

Consortium Skills